BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23228967)

  • 1. FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.
    Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Sangfelt O; Marshall GM
    Leukemia; 2013 Apr; 27(5):1053-62. PubMed ID: 23228967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOTCH1 and/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols.
    Zuurbier L; Homminga I; Calvert V; te Winkel ML; Buijs-Gladdines JG; Kooi C; Smits WK; Sonneveld E; Veerman AJ; Kamps WA; Horstmann M; Petricoin EF; Pieters R; Meijerink JP
    Leukemia; 2010 Dec; 24(12):2014-22. PubMed ID: 20861909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NOTCH1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia.
    Natarajan V; Bandapalli OR; Rajkumar T; Sagar TG; Karunakaran N
    J Pediatr Hematol Oncol; 2015 Jan; 37(1):e23-30. PubMed ID: 25493453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma.
    Park MJ; Taki T; Oda M; Watanabe T; Yumura-Yagi K; Kobayashi R; Suzuki N; Hara J; Horibe K; Hayashi Y
    Br J Haematol; 2009 Apr; 145(2):198-206. PubMed ID: 19245433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor suppressor Fbxw7 regulates TGFβ signaling by targeting TGIF1 for degradation.
    Bengoechea-Alonso MT; Ericsson J
    Oncogene; 2010 Sep; 29(38):5322-8. PubMed ID: 20622901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function.
    Kox C; Zimmermann M; Stanulla M; Leible S; Schrappe M; Ludwig WD; Koehler R; Tolle G; Bandapalli OR; Breit S; Muckenthaler MU; Kulozik AE
    Leukemia; 2010 Dec; 24(12):2005-13. PubMed ID: 20944675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients.
    Kraszewska MD; Dawidowska M; Kosmalska M; Sędek L; Grzeszczak W; Kowalczyk JR; Szczepański T; Witt M;
    Blood Cells Mol Dis; 2013 Jan; 50(1):33-8. PubMed ID: 23040356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study.
    Asnafi V; Buzyn A; Le Noir S; Baleydier F; Simon A; Beldjord K; Reman O; Witz F; Fagot T; Tavernier E; Turlure P; Leguay T; Huguet F; Vernant JP; Daniel F; Béné MC; Ifrah N; Thomas X; Dombret H; Macintyre E
    Blood; 2009 Apr; 113(17):3918-24. PubMed ID: 19109228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma.
    Callens C; Baleydier F; Lengline E; Ben Abdelali R; Petit A; Villarese P; Cieslak A; Minard-Colin V; Rullier A; Moreau A; Baruchel A; Schmitt C; Asnafi V; Bertrand Y; Macintyre E
    J Clin Oncol; 2012 Jun; 30(16):1966-73. PubMed ID: 22547598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fbxw7 regulates tumor apoptosis, growth arrest and the epithelial-to-mesenchymal transition in part through the RhoA signaling pathway in gastric cancer.
    Li H; Wang Z; Zhang W; Qian K; Xu W; Zhang S
    Cancer Lett; 2016 Jan; 370(1):39-55. PubMed ID: 26458995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival.
    Yuan L; Lu L; Yang Y; Sun H; Chen X; Huang Y; Wang X; Zou L; Bao L
    Ann Hematol; 2015 Nov; 94(11):1817-28. PubMed ID: 26341754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fbxw7 contributes to tumor suppression by targeting multiple proteins for ubiquitin-dependent degradation.
    Fujii Y; Yada M; Nishiyama M; Kamura T; Takahashi H; Tsunematsu R; Susaki E; Nakagawa T; Matsumoto A; Nakayama KI
    Cancer Sci; 2006 Aug; 97(8):729-36. PubMed ID: 16863506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of glucocorticoid receptor isoforms expression in acute lymphoblastic leukemia correlate with glucocorticoid resistance.
    Sun X; Fang M; Guan Y; Si Y; Ma L; Wang Y; Jia Z
    Pharmazie; 2015 May; 70(5):316-21. PubMed ID: 26062300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of NOTCH1/FBXW7 mutations on outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on the MRC UKALL 2003 trial.
    Jenkinson S; Koo K; Mansour MR; Goulden N; Vora A; Mitchell C; Wade R; Richards S; Hancock J; Moorman AV; Linch DC; Gale RE
    Leukemia; 2013 Jan; 27(1):41-7. PubMed ID: 22814294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias.
    Song JH; Schnittke N; Zaat A; Walsh CS; Miller CW
    Leuk Res; 2008 Nov; 32(11):1751-5. PubMed ID: 18485478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of mutations in NOTCH1 and FBXW7 in childhood T-ALL treated according to the NOPHO ALL-1992 and ALL-2000 protocols.
    Fogelstrand L; Staffas A; Wasslavik C; Sjögren H; Söderhäll S; Frost BM; Forestier E; Degerman S; Behrendtz M; Heldrup J; Karrman K; Johansson B; Heyman M; Abrahamsson J; Palmqvist L
    Pediatr Blood Cancer; 2014 Mar; 61(3):424-30. PubMed ID: 24424791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.
    Clappier E; Collette S; Grardel N; Girard S; Suarez L; Brunie G; Kaltenbach S; Yakouben K; Mazingue F; Robert A; Boutard P; Plantaz D; Rohrlich P; van Vlierberghe P; Preudhomme C; Otten J; Speleman F; Dastugue N; Suciu S; Benoit Y; Bertrand Y; Cavé H;
    Leukemia; 2010 Dec; 24(12):2023-31. PubMed ID: 20861920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs.
    Yokobori T; Yokoyama Y; Mogi A; Endoh H; Altan B; Kosaka T; Yamaki E; Yajima T; Tomizawa K; Azuma Y; Onozato R; Miyazaki T; Tanaka S; Kuwano H
    Mol Cancer Res; 2014 Jan; 12(1):32-7. PubMed ID: 24165483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
    Mansour MR; Sulis ML; Duke V; Foroni L; Jenkinson S; Koo K; Allen CG; Gale RE; Buck G; Richards S; Paietta E; Rowe JM; Tallman MS; Goldstone AH; Ferrando AA; Linch DC
    J Clin Oncol; 2009 Sep; 27(26):4352-6. PubMed ID: 19635999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
    Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
    Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.